ASHP Advantage: Continuing the Dialogue: Clinical Conversations on Neuromuscular Blockade and Reversal Strategies

In this interprofessional conversation, expert faculty discuss evidence supporting quantitative neuromuscular monitoring (NMM) versus qualitative NMM, which quantitative monitors are available in the U.S., and evidence/guidelines supporting monitoring preferences. NMM and complete neuromuscular blockade (NMB) reversal in patients at high risk for residual NMB (rNMB), including elderly and obese patients, will also be discussed. 

 

To learn more about neuromuscular blockade and reversal visit www.ashpadvantage.com/nmbreversal/.

 

This podcast is provided by ASHP and supported by Merck. 

 

The information presented during the podcast reflects solely the opinions of the presenter.  The information and materials are not, and are not intended as, a comprehensive source of drug information on this topic. The contents of the podcast have not been reviewed by ASHP, and should neither be interpreted as the official policies of ASHP, nor an endorsement of any product(s), nor should they be considered as a substitute for the professional judgment of the pharmacist or physician